ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization
MerDury’s StackDoseTM platform has the technology to generate new products with unique fast-release properties (dissolution
- MerDury’s StackDoseTM platform has the technology to generate new products with unique fast-release properties (dissolution
- Coupled with BioKey’s expertise in orally controlled release technology for developing specialty generic and branded pharmaceutical products, along with its GMP drug manufacturing capabilities, we believe the new technology will enable the Company to develop more IP-protected and brand-name products for commercialization.
- “We are pleased to establish a collaboration with MerDury BioPharma using the proprietary 3D printing StackDoseTM technology for new product development and commercialization,” said Dr. Howard Doong, ABVC Chief Executive Officer.
- “The global oral drug delivery market is estimated to be US$148.2 billion in 2027 and the orally disintegrating tablet market to exceed US$27.2 billion by 2025, according to Research and Market (2022) research report.”